This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
by Zacks Equity Research
Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Why Earnings Season Could Be Great for Biohaven (BHVN)
by Zacks Equity Research
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec
by Zacks Equity Research
Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.
Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
Why Biohaven (BHVN) Might Surprise This Earnings Season
by Zacks Equity Research
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
by Zacks Equity Research
Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Biohaven (BHVN) Stock
by Zacks Equity Research
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
by Zacks Equity Research
Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.
What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Biohaven Pharmaceutical Holding Company Ltd. (BHVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
Bull of the Day: Illumina (ILMN)
by Madeleine Johnson
Invest in the medical space with this DNA sequencing-focused company.
Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.
New Strong Sell Stocks for June 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Express Scripts (ESRX) to Launch Pilot Program, Shares Up
by Zacks Equity Research
Express Scripts (ESRX) aims to add value to patients' diagnosis in return for higher costs.
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
by Zacks Equity Research
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
Masimo Gets CE Mark for NomoLine, Expands in Capnography
by Zacks Equity Research
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) gains on core segmental business, while intense competition raises concern.
Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.